12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
Study sponsor: BioCryst Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-01Actual
Enrollment · participants110Actual
Source updated2025-11-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.